首页> 外文OA文献 >Transfusion of red cells in hematopoietic stem cell transplantation (TRIST): study protocol for a randomized controlled trial
【2h】

Transfusion of red cells in hematopoietic stem cell transplantation (TRIST): study protocol for a randomized controlled trial

机译:造血干细胞移植(TRIST)中的红细胞输注:一项随机对照试验的研究方案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Abstract Background Insight regarding transfusion practices in Hematopoietic Stem cell Transplantation (HSCT) are lacking and the impact of red cell transfusion in this high risk group on outcomes following HSCT are not well appreciated. Red blood cell transfusion can be life-saving, however, liberal use of transfusion in critically ill patients failed to demonstrate significant clinical benefit. A large number of other observational studies have also demonstrated an association between red blood cell transfusions and increased morbidity such as infections and multi organ failure as well as increased mortality. The role of red cell transfusion on the clinical outcomes observed in patients undergoing HSCT remains poorly understood and a prospective randomized study of transfusion is required to gain insight and knowledge on best transfusion practices in this high risk population. Methods This report describes the design and methodological issues of a randomized pilot study evaluating red cell transfusion triggers in the setting of Hematopoietic Stem Cell Transplantation. This study has been funded by a peer review grant from the Canadian Blood Services and is registered on Clinicaltrials.gov NCT01237639. Results In 3 Canadian centres, 100 patients undergoing Hematopoietic Stem Cell Transplantation will be randomized to either a restrictive (target hemoglobin of 70-90 g/L) or liberal (target hemoglobin of 90-110 g/L) red cell transfusion strategy, based daily hemoglobin values up to 100 days post-transplant. The study will stratify participants by centre and type of transplant. The primary goal is to demonstrate study feasibility and we will collect clinical outcomes on 1) Transfusion Requirements, 2) Transplant Related Mortality, 3) Maximum grade of acute Graft versus Host Disease, 4) Veno-occlusive Disease, 5) Serious Infections, 6) Bearman Toxicity Score, 7) Bleeding, 8) Quality of Life, 9) Number of Hospitalizations and 10) Number of Intensive Care Unit (ICU) Admissions. Conclusion Upon completion, this pilot trial will provide preliminary insight into red cell transfusion practice and its influence in hematopoietic stem cell transplant outcomes. The results of this trial will inform the conduct of a larger study.
机译:摘要背景缺乏关于造血干细胞移植(HSCT)中输血实践的见识,并且对这种高风险人群中红细胞输注对HSCT术后结局的影响尚不甚了解。红细胞输血可以挽救生命,但是,在危重患者中大量使用输血未能显示出明显的临床益处。大量其他观察性研究也表明,红细胞输血与发病率增加(如感染和多器官衰竭以及死亡率增加)之间存在关联。红细胞输血对接受HSCT的患者所观察到的临床结果的作用仍知之甚少,需要进行前瞻性的随机输血研究以了解高危人群的最佳输血方法。方法:本报告描述了一项随机试验研究的设计和方法学问题,该研究评估了造血干细胞移植过程中的红细胞输注触发因素。该研究由加拿大血液服务局的同行评审资助,并在Clinicaltrials.gov NCT01237639上注册。结果在加拿大的3个中心,将根据随机选择的限制性红血球(目标血红蛋白为70-90 g / L)或自由血红细胞(目标血红蛋白为90-110 g / L)的100名接受造血干细胞移植的患者,根据移植后100天内每天的血红蛋白值。该研究将按移植中心和类型对参与者进行分层。主要目标是证明研究的可行性,我们将在1)输血要求,2)移植相关死亡率,3)急性移植物抗宿主疾病的最高等级,4)静脉阻塞性疾病,5)严重感染,6中收集临床结果)Bearman毒性评分,7)出血,8)生活质量,9)住院人数,以及10)重症监护病房(ICU)入院人数。结论完成后,该试验性试验将为红细胞输注实践及其对造血干细胞移植结果的影响提供初步见解。该试验的结果将为进行更大的研究提供依据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号